Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-10-31
2006-10-31
Haddad, Maher M. (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C530S327000, C530S328000, C530S329000, C530S330000
Reexamination Certificate
active
07129052
ABSTRACT:
The present invention relates to a peptide comprising the sequence R1-X1-X2-X3-X4-R2, wherein X1is selected from the group consisting of N, Q, D and S; X2is selected from the group consisting of V, I and L; X3is selected from the group consisting of R and K; and X4is selected from the group consisting of V, I, L and F; R1is a hydrogen or a peptide of 1 to 6 amino acids, and acyl or an aryl group; and R2is a peptide of 1 to 3 amino acids, a hydroxide or an amide. The invention also relates to partial or full retro-inverso peptides comprising the above sequences. The invention also relates to peptide-substrate combination comprising a substrate suitable for cell growth and the peptide of the invention, and to a vascular graft and an artificial blood vessel comprising the peptide-substrate combination. The invention also relates to a pharmaceutical composition and a peptide conjugate comprising the peptide of the invention. The invention also relates to a method of inhibiting adhesion of a cell expressing α3β1 integrin to an cellular matrix, inhibiting α3β1-integrin-mediated cell motility, inhibiting α3β1-integrin mediated cell proliferation, promoting α3β1-integrin mediated cell proliferation and inhibiting angiogenesis utilizing the peptides of the invention.
REFERENCES:
patent: 5696229 (1997-12-01), Laurie et al.
patent: 5770563 (1998-06-01), Roberts et al.
patent: 5789184 (1998-08-01), Fowlkes et al.
patent: 6020312 (2000-02-01), Edwards
patent: 10257896 (1998-09-01), None
patent: WO 90 03983 (1990-04-01), None
patent: WO 92/09628 (1992-06-01), None
patent: WO 98/42737 (1998-10-01), None
Prater et al. The properdin-like type I repeats of human thrombospondin contain a cell attachment siteJ Cell Biol. 112(5):1031-40, 1991.
Li et al. An all-D amino acid peptide model of alpha1(IV)531-543 from type IV collagen binds the alpha3beta 1 integrin and mediates tumor cell adhesion, spreading, and motility. Biochemistry. 36(49):15404-15410, 1997.
Nomizu et al. Identification of cell binding sequences in mouse laminin gamma1 chain by systematic peptide screening.J Biol Chem. 272(51):32198-205, 1997.
Chandrasekaran et al. Pro-adhesive and chemotactic activities of thrombospondin-1 for breast carcinoma cells are mediated b alpha3beta1 integrin and regulated by insulin-like growth factor-1 and CD98, J Biol Chem. 274(16):11408-16, 1999.
krtzsch et al. Identification of an alpha(3)beta(1) integrin recognition sequence in thrombospondin-1. J Biol Chem. 274(34):24080-6, 1999.
Khan et al Role of laminin in matrix induction of macrophage urokinase-type plasminogen activator and 92-kDa metalloproteinase expression. J Biol Chem. 272(13):8270-5., 1997.
Krutzsch Henry C.
Roberts David D.
Haddad Maher M.
The United States of America as represented by the Department of
Townsend and Townsend / and Crew LLP
LandOfFree
Peptides and their utility in modulation of behavior of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides and their utility in modulation of behavior of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides and their utility in modulation of behavior of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3638217